期刊
BLOOD
卷 119, 期 1, 页码 296-307出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-06-364265
关键词
-
类别
资金
- National Cancer Institute (NCI) [U24-CA76518]
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- NHLBI [5U01HL069294]
- NCI
- Health Resources and Services Administration [HHSH234200637015C]
- Office of Naval Research [N00014-061-0704, N00014-08-1-0058]
- Allos Inc
- Amgen Inc
- Angioblast
- Ariad
- Be the Match Foundation
- Blue Cross and Blue Shield Association
- Buchanan Family Foundation
- CaridianBCT
- Celgene Corporation
- CellGenix, GmbH
- Children's Leukemia Research Association
- Fresenius-Biotech North America Inc
- Gamida Cell Teva Joint Venture Ltd
- Genentech Inc
- Genzyme Corporation
- GlaxoSmithKline
- Kiadis Pharma
- Leukemia & Lymphoma Society
- Medical College of Wisconsin
- Millennium Pharmaceuticals Inc
- Milliman USA Inc
- Miltenyi Biotec Inc
- National Marrow Donor Program
- Optum Healthcare Solutions Inc
- Otsuka America Pharmaceutical Inc
- Seattle Genetics
- Sigma-Tau Pharmaceuticals
- Soligenix Inc
- Swedish Orphan Biovitrum
- THERAKOS Inc
- Wellpoint Inc
Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (19992005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen on AGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, orRIC + PBSCs had lower risks of grades B-D AGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients. (Blood. 2012; 119(1): 296-307)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据